76 related articles for article (PubMed ID: 36689726)
21. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
22. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Tam CS; Allan JN; Siddiqi T; Kipps TJ; Jacobs R; Opat S; Barr PM; Tedeschi A; Trentin L; Bannerji R; Jackson S; Kuss BJ; Moreno C; Szafer-Glusman E; Russell K; Zhou C; Ninomoto J; Dean JP; Wierda WG; Ghia P
Blood; 2022 Jun; 139(22):3278-3289. PubMed ID: 35196370
[TBL] [Abstract][Full Text] [Related]
23. The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.
Pinney JJ; Blick-Nitko SK; Baran AM; Peterson DR; Whitehead HE; Izumi R; Munugalavadla V; Van DerMeid KR; Barr PM; Zent CS; Elliott MR; Chu CC
Haematologica; 2022 Jun; 107(6):1460-1465. PubMed ID: 35172559
[No Abstract] [Full Text] [Related]
24. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
Wierda WG; Rawstron A; Cymbalista F; Badoux X; Rossi D; Brown JR; Egle A; Abello V; Cervera Ceballos E; Herishanu Y; Mulligan SP; Niemann CU; Diong CP; Soysal T; Suzuki R; Tran HTT; Wu SJ; Owen C; Stilgenbauer S; Ghia P; Hillmen P
Leukemia; 2021 Nov; 35(11):3059-3072. PubMed ID: 34168283
[TBL] [Abstract][Full Text] [Related]
25. Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.
Pinney JJ; Rivera-Escalera F; Chu CC; Whitehead HE; VanDerMeid KR; Nelson AM; Barbeau MC; Zent CS; Elliott MR
Blood; 2020 Oct; 136(18):2065-2079. PubMed ID: 32556153
[TBL] [Abstract][Full Text] [Related]
26. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Shanafelt TD; Wang XV; Kay NE; Hanson CA; O'Brien S; Barrientos J; Jelinek DF; Braggio E; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Little RF; Erba H; Stone RM; Litzow M; Tallman M
N Engl J Med; 2019 Aug; 381(5):432-443. PubMed ID: 31365801
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Burger JA; Sivina M; Jain N; Kim E; Kadia T; Estrov Z; Nogueras-Gonzalez GM; Huang X; Jorgensen J; Li J; Cheng M; Clow F; Ohanian M; Andreeff M; Mathew T; Thompson P; Kantarjian H; O'Brien S; Wierda WG; Ferrajoli A; Keating MJ
Blood; 2019 Mar; 133(10):1011-1019. PubMed ID: 30530801
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Woyach JA; Ruppert AS; Heerema NA; Zhao W; Booth AM; Ding W; Bartlett NL; Brander DM; Barr PM; Rogers KA; Parikh SA; Coutre S; Hurria A; Brown JR; Lozanski G; Blachly JS; Ozer HG; Major-Elechi B; Fruth B; Nattam S; Larson RA; Erba H; Litzow M; Owen C; Kuzma C; Abramson JS; Little RF; Smith SE; Stone RM; Mandrekar SJ; Byrd JC
N Engl J Med; 2018 Dec; 379(26):2517-2528. PubMed ID: 30501481
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.
Drennan S; Chiodin G; D'Avola A; Tracy I; Johnson PW; Trentin L; Steele AJ; Packham G; Stevenson FK; Forconi F
Clin Cancer Res; 2019 Apr; 25(8):2503-2512. PubMed ID: 30373751
[TBL] [Abstract][Full Text] [Related]
31. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
[TBL] [Abstract][Full Text] [Related]
32. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Hallek M; Cheson BD; Catovsky D; Caligaris-Cappio F; Dighiero G; Döhner H; Hillmen P; Keating M; Montserrat E; Chiorazzi N; Stilgenbauer S; Rai KR; Byrd JC; Eichhorst B; O'Brien S; Robak T; Seymour JF; Kipps TJ
Blood; 2018 Jun; 131(25):2745-2760. PubMed ID: 29540348
[TBL] [Abstract][Full Text] [Related]
33. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable
Golay J; Ubiali G; Introna M
Haematologica; 2017 Oct; 102(10):e400-e403. PubMed ID: 28642301
[No Abstract] [Full Text] [Related]
34. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).
Rummel M; Kim TM; Aversa F; Brugger W; Capochiani E; Plenteda C; Re F; Trask P; Osborne S; Smith R; Grigg A
Ann Oncol; 2017 Apr; 28(4):836-842. PubMed ID: 28031173
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
[TBL] [Abstract][Full Text] [Related]
36. Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data.
Danese MD; Reyes CM; Gleeson ML; Halperin M; Skettino SL; Mikhael J
Med Care; 2016 Apr; 54(4):343-9. PubMed ID: 26759977
[TBL] [Abstract][Full Text] [Related]
37. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Skarzynski M; Niemann CU; Lee YS; Martyr S; Maric I; Salem D; Stetler-Stevenson M; Marti GE; Calvo KR; Yuan C; Valdez J; Soto S; Farooqui MZ; Herman SE; Wiestner A
Clin Cancer Res; 2016 Jan; 22(1):86-95. PubMed ID: 26283682
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
[TBL] [Abstract][Full Text] [Related]
39. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
[TBL] [Abstract][Full Text] [Related]
40. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Woyach JA; Smucker K; Smith LL; Lozanski A; Zhong Y; Ruppert AS; Lucas D; Williams K; Zhao W; Rassenti L; Ghia E; Kipps TJ; Mantel R; Jones J; Flynn J; Maddocks K; O'Brien S; Furman RR; James DF; Clow F; Lozanski G; Johnson AJ; Byrd JC
Blood; 2014 Mar; 123(12):1810-7. PubMed ID: 24415539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
